Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 6/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 6/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.41 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083345 | 0.86 | KIF11 (0.46) | IDO1P2RX7 | |
| SCHEMBL19251186 | 0.83 | PTPN7 (0.41) | PTPN7DUSP3ARIDO1SLC6A4 | |
| SCHEMBL19240325 | 0.83 | IDO1 (0.42) | IDO1 | |
| SCHEMBL19251076 | 0.82 | RXRA (0.46) | PTPN7DUSP3ARIDO1SLC6A4 | |
| SCHEMBL12509484 | 0.79 | SLC6A4 (0.50) | PTPN7DUSP3ARIDO1SLC6A4 | |
| SCHEMBL1716084 | 0.79 | IDO1 (0.67) | PTPN7DUSP3IDO1 | |
| SCHEMBL19250945 | 0.77 | CYP1A2 (0.41) | RXRAGRIN1GRIN2B | |
| SCHEMBL19250949 | 0.77 | CA3 (0.41) | — | |
| SCHEMBL19251061 | 0.77 | CNR2 (0.41) | IDO1SLC6A4 | |
| SCHEMBL19251029 | 0.77 | NPC1 (0.37) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647683-B2 | Hsp70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190241526-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2019-08-08 | — | — | US | disclosed |
| US-20180170883-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2018-06-21 | — | — | US | disclosed |
| US-9878987-B2 | HSP70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241526-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | PTPN7 3495/4885DUSP3 1829/4885AR 826/4885 |
| US-20180170883-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | PTPN7 3495/4885DUSP3 1829/4885AR 826/4885 |
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | PTPN7 3778/4885DUSP3 2542/4885AR 715/4885 |
| US-10647683-B2 | Hsp70 modulators and methods for making and using the same | HSPA2, HSP90AA1, HSP90AB1 | PTPN7 3495/4885DUSP3 1829/4885AR 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.